Related Experiment Video

Updated: Feb 11, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Development and validation of a risk stratification score for new-onset atrial fibrillation in STEMI patients

Annamaria Mazzone1, Marco Scalese2, Umberto Paradossi1

  • 1Fondazione G. Monasterio CNR-Regione Toscana Pisa, Massa, Italy.

International Journal of Clinical Practice
|April 18, 2018
PubMed

Insights

A new ALBO risk score identifies patients at high risk for new-onset atrial fibrillation (NOAF) after ST-segment elevation myocardial infarction (STEMI) and primary percutaneous coronary intervention (pPCI). This tool aids in early intervention for better patient outcomes.

Area of Science:

  • Cardiology
  • Biomarkers
  • Clinical Risk Stratification

Background:

  • New-onset atrial fibrillation (NOAF) is a frequent complication in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (pPCI).
  • NOAF is associated with adverse in-hospital and long-term prognosis.
  • Predictive tools for early NOAF detection post-pPCI are needed.

Purpose of the Study:

  • To develop and validate a risk score for early NOAF incidence.
  • The score is based on clinical factors and routine blood biomarkers.
  • To identify patients for prompt intervention after pPCI.

Main Methods:

  • A risk score was developed in 1135 STEMI patients undergoing pPCI.
  • External validation was performed in a separate cohort of 771 STEMI patients.
  • Multivariate Cox-regression identified predictors: age, leukocyte count, BNP, and obesity.

Main Results:

  • The ALBO risk score (Age, Leucocyte, BNP, Obesity) was derived.
  • High predictive accuracy was observed in both derivation (C-statistic 0.734) and validation (0.76) cohorts.
  • A score >4 identified a high-risk tertile with NOAF incidence of 30.8% and 27.4%.

Conclusions:

  • The ALBO risk score effectively identifies patients at high risk for NOAF post-pPCI.
  • It utilizes readily available clinical and biomarker data.
  • Facilitates timely intervention strategies for high-risk individuals.
Abstract

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
Robotic Ablation of Atrial Fibrillation11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

20.2K

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.0K
Amyloid Fibrils03:03

Amyloid Fibrils

6.5K
Reliability and Validity01:29

Reliability and Validity

Reliability and validity are two important considerations that must be made with any type of data collection. Reliability refers to the ability to consistently produce a given result. In the context of psychological research, this would mean that any instruments or tools used to collect data do so in consistent, reproducible ways.
14.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
363
Introduction to z Scores01:06

Introduction to z Scores

A z score (or standardized value) is measured in units of the standard deviation. It tells you how many standard deviations the value x is above (to the right of) or below (to the left of) the mean, μ. Values of x that are larger than the mean have positive z scores, and values of x that are smaller than the mean have negative z scores. If x equals the mean, then x has a zero z score. It is important to note that the mean of the z scores is zero, and the standard deviation is one.
z scores...
11.3K
Introduction to z Scores01:05

Introduction to z Scores

A z score (or standardized value) is measured in units of the standard deviation. It indicates how many standard deviations the value x is above (to the right of) or below (to the left of) the mean, μ. Values of x that are larger than the mean have positive z scores, and values of x that are smaller than the mean have negative z scores. If x equals the mean, then x has a zero z score. It is important to note that the mean of the z scores is zero, and the standard deviation is one.
z scores...
1.4K